On March 22, 2023 Anocca reported that it will attend 6th Annual Neoantigen Summit Europe (Press release, Anocca, MAR 22, 2023, View Source [SID1234629152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reagan Jarvis, our CEO, is presenting ‘Showcasing Individualised Neoantigen Discovery Platform’ at the TCR-Based Therapies for Solid Tumours, where he talks about understanding HLA-restricted neoantigen target complexity with cell-based assays, validating neoantigen targets with T-cell Receptor reagents derived by rapid
multiplex discovery and considering TCR potency and safety trade-off for HLA-restricted neoantigens.

On March 22, 2023 Anocca reported it wil attend 2023 Cell & Gene Meeting on the Med (Press release, Anocca, MAR 22, 2023, View Source [SID1234629151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We are delighted to be one of the sponsors of this year’s 2023 Cell & Gene Meeting on the Med, with Reagan Jarvis, our CEO and Brian McGee, our CBO presenting Anocca, our technology platforms and our pipeline of novel T-cell therapies.

On March 22, 2023 Anocca reported that it will attend TCR-Based Therapies for Solid Tumours summit (Press release, Anocca, MAR 22, 2023, View Source [SID1234629150]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reagan Jarvis, our CEO, is presenting ‘Systematic Isolation & Characterization of Clinical TCR Candidates’ at the TCR-Based Therapies for Solid Tumours, where he discusses native and optimized TCR frameworks, TCR cross-reactivity including insights and practical benchmarks and preventing TCR allo-reactivity.

On March 21, 2023 HLB Life Science reported that it received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial plan for the anticancer drug ‘Pyrotinib’ (Press release, HLB Life Science, MAR 21, 2023, View Source;word=&page=1&v=381 [SID1234649274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The title of the clinical trial is ‘A randomized, active-controlled, open-label, multi-center phase 3 clinical trial to evaluate the efficacy and safety of Pyrotinib + Capecitabine combination compared to Lapatinib + Capecitabine combination in patients with HER2-positive metastatic or recurrent breast cancer’. The clinical trial will be conducted on 204 patients in 11 hospitals in Korea (total of 12 hospitals) excluding Seoul National University Hospital. (Clinical period: 36 months from the date of approval by the Institutional Review Board)

The company plans to confirm the progression-free survival period (PFS, primary endpoint) through this clinical trial.

Pyrotinib is a small molecule compound independently developed by Hengrui Pharmaceutical of China, and is an oral targeted anticancer drug targeting EGFR/HER2/HER4. In 2020, it received official approval in China as a second-line treatment for HER2 metastatic breast cancer. In

2020, HLB Life Science signed an exclusive licensing agreement for Pyrotinib in Korea with Hangseo Pharmaceutical, and has exclusive rights to the clinical development and sales of Pyrotinib as a treatment for various cancers, including breast cancer and lung cancer, in Korea.

HLB Life Science applied for the clinical trial to the Ministry of Food and Drug Safety on July 29, 2022.

On March 21, 2023 EpicentRx Inc. ("EpicentRx"), a clinical stage biopharmaceutical company, reported the publication of a review article on its small molecule, RRx-001, a direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegenerative diseases and other inflammatory conditions (Press release, EpicentRx, MAR 21, 2023, View Source [SID1234629107]). The article is entitled, A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is the first publication from the collaboration between EpicentRx and Associate Professor Richard Gordon’s team based at the Queensland University of Technology’s Centre for Microbiome Research (CMR) and the Translational Research Institute (TRI). Dr. Gordon is an internationally recognized expert on inflammasome signaling in neurodegenerative diseases. EpicentRx and Dr. Gordon’s team were awarded research grants from the Michael J. Fox Foundation (MJFF), Shake It Up Australia Foundation, and Fight MND to study the neuroprotective effects of RRx-001 in Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS).

RRx-001 is one of the most advanced direct NLRP3 inflammasome inhibitors in clinical development and has been evaluated in over 300 multimorbid cancer patients both alone and in combination with other therapies. Currently in a Phase 3 trial for the treatment of small cell lung cancer, RRx-001 is also in late-stage development as an anti-mucositis agent in head and neck cancer and as a medical countermeasure against acute radiation syndrome (ARS) in the event of nuclear fallout. RRx-001 has been evaluated in multiple independent studies for conditions where immune and inflammasome activation contribute to disease pathology. These include cancer, myocardial infarction, pulmonary hypertension, acute kidney injury, acute radiation syndrome (ARS), malaria, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.

Lead author Dr. Nanthini Jayabalan, a senior researcher working on the CNS RRx-001 program in Dr. Gordon’s lab said, "Our review article synthesizes the wealth of data on RRx-001 to date, which supports its disease-modifying potential in a range of conditions."

Added Dr. Gordon: "Emerging evidence suggests, chronic, unresolving inflammation is present in most if not all neurological diseases, and this makes RRx-001 an attractive therapeutic agent for neuroprotection given its track record in human studies."